FTB Advisors Inc. reduced its stake in AstraZeneca plc (NYSE:AZN) by 39.1% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,535 shares of the company’s stock after selling 2,270 shares during the quarter. FTB Advisors Inc.’s holdings in AstraZeneca were worth $457,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. HPM Partners LLC increased its position in shares of AstraZeneca by 50.2% during the 2nd quarter. HPM Partners LLC now owns 34,813 shares of the company’s stock valued at $1,222,000 after purchasing an additional 11,629 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of AstraZeneca during the 2nd quarter valued at $10,519,000. Vident Investment Advisory LLC increased its position in shares of AstraZeneca by 30.5% during the 2nd quarter. Vident Investment Advisory LLC now owns 69,090 shares of the company’s stock valued at $2,426,000 after purchasing an additional 16,137 shares during the last quarter. Baird Financial Group Inc. increased its position in shares of AstraZeneca by 12.0% during the 2nd quarter. Baird Financial Group Inc. now owns 56,959 shares of the company’s stock valued at $2,000,000 after purchasing an additional 6,092 shares during the last quarter. Finally, Argent Trust Co purchased a new stake in shares of AstraZeneca during the 2nd quarter valued at $536,000. 16.10% of the stock is owned by hedge funds and other institutional investors.
In other news, major shareholder Plc Astrazeneca purchased 600,000 shares of the business’s stock in a transaction dated Monday, October 22nd. The stock was bought at an average price of $5.00 per share, for a total transaction of $3,000,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website.
Shares of AstraZeneca stock opened at $40.97 on Friday. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08. The firm has a market cap of $99.31 billion, a PE ratio of 9.57, a price-to-earnings-growth ratio of 2.09 and a beta of 0.57. AstraZeneca plc has a 1 year low of $31.99 and a 1 year high of $41.28.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 8th. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.33 by $0.38. The company had revenue of $5.34 billion during the quarter, compared to the consensus estimate of $5.26 billion. AstraZeneca had a return on equity of 29.89% and a net margin of 11.98%. The firm’s quarterly revenue was down 14.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.12 EPS. Equities analysts expect that AstraZeneca plc will post 1.67 earnings per share for the current fiscal year.
AZN has been the subject of several research analyst reports. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a research report on Monday, July 16th. ValuEngine raised AstraZeneca from a “hold” rating to a “buy” rating in a research report on Saturday, July 28th. Jefferies Financial Group lowered AstraZeneca from a “buy” rating to a “hold” rating in a research report on Thursday, August 16th. Guggenheim initiated coverage on AstraZeneca in a research report on Monday, October 8th. They set a “buy” rating for the company. Finally, Wolfe Research initiated coverage on AstraZeneca in a research report on Tuesday, October 23rd. They set an “outperform” rating for the company. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $40.34.
WARNING: This report was published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.thelincolnianonline.com/2018/11/10/ftb-advisors-inc-has-457000-position-in-astrazeneca-plc-azn.html.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
See Also: What is the Rule of 72?
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.